Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Oct. 04, 2016 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that in conjunction with today’s announcement on an exclusive license and collaboration agreement with Sarepta Therapeutics for European rights to Summit’s utrophin modulator pipeline for the treatment of DMD, Summit will be holding a conference call at 1:00pm BST / 8:00am EDT.

To participate in the conference call, please dial +44(0)20 3427 1918 (UK and international participants) or +1 646 254 3365 (US local number) and use the conference confirmation code 6907795. Investors may also access a live audio webcast of the call via the investors section of the Company’s website www.summitplc.com. A replay of the webcast will be available shortly after the presentation finishes.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

-END-